- XAV-939
- ABT-888 (Veliparib)
- BMN-673 8R,9S
- MK-4827
- PJ34
BYK 204165PARP-1 inhibitor,potent and selective |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
BYK 204165 Dilution Calculator
calculate
BYK 204165 Molarity Calculator
calculate
Cas No. | 1104546-89-5 | SDF | Download SDF |
Chemical Name | (4E)-4-[(1-methylpyrrol-2-yl)methylidene]isoquinoline-1,3-dione | ||
Canonical SMILES | CN1C=CC=C1C=C2C3=CC=CC=C3C(=O)NC2=O | ||
Formula | C15H12N2O2 | M.Wt | 252.27 |
Solubility | <25.23mg l="" in="" dmso="">25.23mg> | Storage | Desiccate at 4°C |
Physical Appearance | Yellow solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
BYK 204165 is a potent and selective poly(ADP-ribose) polymerase (PARP)-1 inhibitor with pIC50 values of 5.38 and 7.35 for PARP-2 and PARP-1 respectively [1].PARP1 is a nuclear enzyme activated by strand breaks in DNA and involved in the regulation of various cell processes such as DNA repair, apoptosis, organ dysfunction or necrosis [1].BYK 204165 (PARP inhibitor XIV) is a cell-permeable isoquinolinedione compound that potently and selectively inhibits PARP1. BYK 204165’s potency is similar or higher than most current standard PARP-1 inhibitors (just slightly lower than PJ34), and it is 100-fold selective for PARP-1 over PARP-2 [1].BYK 204165 was not tested in vivo because of BYK its poor water solubility.References:[1]. Eltze T, Boer R, Wagner T, et al. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. Mol Pharmacol, 2008, 74(6): 1587-98.